>
Company >
History
-
2024
-
Signed an exclusive distribution contract with MicroDigital Co., Ltd. for the high-sensitivity point-of-care diagnostic device ‘JWelix Q6
-
2023
-
Completion of relocation to new headquarters in Gwacheon, strengthening 'R&D-focused' management system
-
Korean patent registration for sepsis early diagnosis biomarker specific binding antibody
-
2022
-
Signed the MOU with Micro-Digital for high-sensitivity on-site diagnostic analyzer ‘JWELICS Q6’
-
2021
-
Signed a non-cxclusive license agreement with Immunovia(Sweden) for the patent 'diagnostic biomarker of pancreatic cancer'
-
World's 1st Europeon&Chinese patent registration of diagnostic technique for sepsis
-
Equity invesrment to 'Onebiomed', a Singapore molecular diagnostic company
-
2020
-
Merged as a subsidiary in JW Life-Science
-
Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
-
Obtainment of the patents for a diagnosis technology of septicemia both in US and Japan
-
2019
-
Exclusive supply contract with JEOL biochemical equipment
-
2018
-
Launched SANGRAY, the first X-ray blood irradiator in Korea
-
Released steam sterilizers JW-SS360, JW-SS270
-
Early detection of pancreatic cancer "Multiple biomarker diagnostic kit" Technology transfer contract signed (Yonsei University)
-
2016
-
Signed a contract for early diagnosis of sepsis infection technology transfer ((Re)Pharmaceutical Bioconvergence Research Group)
-
Established JW Bioscience
